Publication date context February 19 2026. A multicenter exploratory evaluation of the Zenicom digital therapeutic device for aphasia after stroke is listed as recruiting and is the subject of this regulatory style news report. The trial compares the Zenicom device to conventional speech therapy and lists Seoul National University Bundang Hospital, Konkuk University Hospital, and Samsung Medical Center as sponsors. The ClinicalTrials.gov entry NCT07397923 is the cited source for the status presented here. This article provides publicly available information and notes the need for further data as the study progresses.
In this article What changed, How Zenicom fits in, What evidence exists, Who is involved, Safety and regulatory considerations.
What changed with Zenicom in this exploration?
The public trial listing indicates an exploratory evaluation of the Zenicom digital therapeutic device for aphasia after stroke. The intervention is described as the Zenicom device, with conventional speech therapy as the comparator. The record identifies sponsor institutions and notes a multicenter design. The trial status is recruiting as of February 19 2026, and the link to the registry is NCT07397923 on ClinicalTrials.gov. The available text provides no outcome data or efficacy claims at this stage.
How does Zenicom fit into therapy for subacute stroke aphasia?
Zenicom is described in the record as a digital therapeutic device under evaluation for aphasia following stroke in the subacute phase. The text does not disclose mechanism of action or device performance claims. In this context the device would be evaluated alongside conventional speech therapy as part of the trial protocol, and details on mode of delivery are not provided in the available text.
What evidence is available at this stage?
The material provided for this report shows only registry information. It confirms an exploratory evaluation and lists the Zenicom device as the intervention and conventional speech therapy as the comparator. There are no published outcomes or safety data in the supplied text. Readers should monitor the ClinicalTrials.gov entry and sponsor communications for updates.
Who is involved in the study and who may be affected?
The trial is described as multicenter and lists sponsor institutions. The exact inclusion criteria are not disclosed in the available text. Participants are patients with aphasia after stroke in the subacute period, as implied by the focus of the study. Clinicians and trial staff at the sponsoring centers would be involved in trial execution and reporting.
What safety and regulatory considerations apply to Zenicom at this stage?
At this early stage the record does not provide safety data or specific performance claims. Regulatory style analysis requires a clear intended purpose, performance profile and safety information before market authorization. The current information shows an exploratory approach suitable for investigation under applicable medical device regulations and good clinical practice. Sponsors should prepare risk management documentation, device labeling and oversight plans should the device advance.
FAQ
1. What is Zenicom? The record describes it as a digital therapeutic device under evaluation for aphasia after stroke in the subacute period.
2. What is the trial status? The registry lists recruiting as of February 2026.
3. Where is the trial conducted? Sponsor institutions include three hospitals and the design is multicenter.
4. How can I learn more? See the ClinicalTrials.gov entry NCT07397923 and the sponsor institutions for updates.
Conclusion
Zenicom remains in the early exploratory evaluation phase for subacute stroke aphasia. The information available shows a multicenter trial with Zenicom as the intervention and conventional speech therapy as the comparator. No results are published in the provided text. Stakeholders should monitor updates from ClinicalTrials.gov and sponsor communications for new data or regulatory submissions.
Disclaimer
This article is intended for clinical, quality and regulatory professionals. It is not legal advice or medical guidance. It summarizes publicly available information and should not be used to drive clinical decisions.
https://clinicaltrials.gov/study/NCT07397923?term=medical+device